Intravitreal injection of aflibercept, an anti-VEGF antagonist, down-regulates plasma von Willebrand factor in patients with age-related macular degeneration

Abstract We investigated the association between von Willebrand factor (VWF) and exudative age-related macular degeneration (AMD) in 114 Japanese patients. Intravitreal injection of vascular endothelial growth factor (VEGF) inhibitor is the most effective therapy for AMD. Therefore, we analyzed chan...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mariko Yamashita, Masanori Matsumoto, Masaki Hayakawa, Kazuya Sakai, Yoshihiro Fujimura, Nahoko Ogata
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2018
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/995d2842aecf46f6b17a2d1916c57f4d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:995d2842aecf46f6b17a2d1916c57f4d
record_format	dspace
spelling	oai:doaj.org-article:995d2842aecf46f6b17a2d1916c57f4d2021-12-02T15:08:23ZIntravitreal injection of aflibercept, an anti-VEGF antagonist, down-regulates plasma von Willebrand factor in patients with age-related macular degeneration10.1038/s41598-018-19473-02045-2322https://doaj.org/article/995d2842aecf46f6b17a2d1916c57f4d2018-01-01T00:00:00Zhttps://doi.org/10.1038/s41598-018-19473-0https://doaj.org/toc/2045-2322Abstract We investigated the association between von Willebrand factor (VWF) and exudative age-related macular degeneration (AMD) in 114 Japanese patients. Intravitreal injection of vascular endothelial growth factor (VEGF) inhibitor is the most effective therapy for AMD. Therefore, we analyzed changes of VWF antigen (VWF:Ag) and VWF multimers (VWFMs) after intravitreal injection of aflibercept, an anti-VEGF antagonist. The relationship between polymorphisms in complement factor H (p.Y402H and p.I62V) and AMD was previously reported. In our patients, p.I62V, but not p.Y402H, was significantly associated with an increased risk of AMD. Pre-treatment plasma levels of VWF:Ag in patients with AMD were significantly higher than those in controls. Unusually large VWFMs (UL-VWFMs) were detected in the majority of AMD patients with concurrent vitreous or subretinal hemorrhage. After intravitreal injection of aflibercept, plasma levels of VWF:Ag and VEGF-A were significantly decreased. UL-VWFMs disappeared after aflibercept injection in three cases, but persisted even 1 month after injection in the other five cases. In conclusion, plasma VWF:Ag levels were significantly elevated in patients with AMD, and decreased after intravitreal aflibercept injection. VWF may play an important role in the pathophysiology of AMD, and aflibercept might improve AMD by reducing plasma levels of VWF in addition to VEGF-A.Mariko YamashitaMasanori MatsumotoMasaki HayakawaKazuya SakaiYoshihiro FujimuraNahoko OgataNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 8, Iss 1, Pp 1-9 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Mariko Yamashita Masanori Matsumoto Masaki Hayakawa Kazuya Sakai Yoshihiro Fujimura Nahoko Ogata Intravitreal injection of aflibercept, an anti-VEGF antagonist, down-regulates plasma von Willebrand factor in patients with age-related macular degeneration
description	Abstract We investigated the association between von Willebrand factor (VWF) and exudative age-related macular degeneration (AMD) in 114 Japanese patients. Intravitreal injection of vascular endothelial growth factor (VEGF) inhibitor is the most effective therapy for AMD. Therefore, we analyzed changes of VWF antigen (VWF:Ag) and VWF multimers (VWFMs) after intravitreal injection of aflibercept, an anti-VEGF antagonist. The relationship between polymorphisms in complement factor H (p.Y402H and p.I62V) and AMD was previously reported. In our patients, p.I62V, but not p.Y402H, was significantly associated with an increased risk of AMD. Pre-treatment plasma levels of VWF:Ag in patients with AMD were significantly higher than those in controls. Unusually large VWFMs (UL-VWFMs) were detected in the majority of AMD patients with concurrent vitreous or subretinal hemorrhage. After intravitreal injection of aflibercept, plasma levels of VWF:Ag and VEGF-A were significantly decreased. UL-VWFMs disappeared after aflibercept injection in three cases, but persisted even 1 month after injection in the other five cases. In conclusion, plasma VWF:Ag levels were significantly elevated in patients with AMD, and decreased after intravitreal aflibercept injection. VWF may play an important role in the pathophysiology of AMD, and aflibercept might improve AMD by reducing plasma levels of VWF in addition to VEGF-A.
format	article
author	Mariko Yamashita Masanori Matsumoto Masaki Hayakawa Kazuya Sakai Yoshihiro Fujimura Nahoko Ogata
author_facet	Mariko Yamashita Masanori Matsumoto Masaki Hayakawa Kazuya Sakai Yoshihiro Fujimura Nahoko Ogata
author_sort	Mariko Yamashita
title	Intravitreal injection of aflibercept, an anti-VEGF antagonist, down-regulates plasma von Willebrand factor in patients with age-related macular degeneration
title_short	Intravitreal injection of aflibercept, an anti-VEGF antagonist, down-regulates plasma von Willebrand factor in patients with age-related macular degeneration
title_full	Intravitreal injection of aflibercept, an anti-VEGF antagonist, down-regulates plasma von Willebrand factor in patients with age-related macular degeneration
title_fullStr	Intravitreal injection of aflibercept, an anti-VEGF antagonist, down-regulates plasma von Willebrand factor in patients with age-related macular degeneration
title_full_unstemmed	Intravitreal injection of aflibercept, an anti-VEGF antagonist, down-regulates plasma von Willebrand factor in patients with age-related macular degeneration
title_sort	intravitreal injection of aflibercept, an anti-vegf antagonist, down-regulates plasma von willebrand factor in patients with age-related macular degeneration
publisher	Nature Portfolio
publishDate	2018
url	https://doaj.org/article/995d2842aecf46f6b17a2d1916c57f4d
work_keys_str_mv	AT marikoyamashita intravitrealinjectionofafliberceptanantivegfantagonistdownregulatesplasmavonwillebrandfactorinpatientswithagerelatedmaculardegeneration AT masanorimatsumoto intravitrealinjectionofafliberceptanantivegfantagonistdownregulatesplasmavonwillebrandfactorinpatientswithagerelatedmaculardegeneration AT masakihayakawa intravitrealinjectionofafliberceptanantivegfantagonistdownregulatesplasmavonwillebrandfactorinpatientswithagerelatedmaculardegeneration AT kazuyasakai intravitrealinjectionofafliberceptanantivegfantagonistdownregulatesplasmavonwillebrandfactorinpatientswithagerelatedmaculardegeneration AT yoshihirofujimura intravitrealinjectionofafliberceptanantivegfantagonistdownregulatesplasmavonwillebrandfactorinpatientswithagerelatedmaculardegeneration AT nahokoogata intravitrealinjectionofafliberceptanantivegfantagonistdownregulatesplasmavonwillebrandfactorinpatientswithagerelatedmaculardegeneration
_version_	1718388137651077120

Intravitreal injection of aflibercept, an anti-VEGF antagonist, down-regulates plasma von Willebrand factor in patients with age-related macular degeneration

Ejemplares similares